Long, B. R., Veron, P., Kuranda, K., Hardet, R., Mitchell, N., Hayes, G. M., . . . Schweighardt, B. (2021). Early Phase Clinical Immunogenicity of Valoctocogene Roxaparvovec, an AAV5-Mediated Gene Therapy for Hemophilia A. Mol Ther.
シカゴスタイル引用形Long, Brian R., et al. "Early Phase Clinical Immunogenicity of Valoctocogene Roxaparvovec, an AAV5-Mediated Gene Therapy for Hemophilia A." Mol Ther 2021.
MLA引用形式Long, Brian R., et al. "Early Phase Clinical Immunogenicity of Valoctocogene Roxaparvovec, an AAV5-Mediated Gene Therapy for Hemophilia A." Mol Ther 2021.
警告: この引用は必ずしも正確ではありません.